Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide

Next Previous
Search
Trial Profile

A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dinutuximab (Primary) ; Lenalidomide (Primary) ; Natural killer cell therapy (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Acronyms NANT

    • Most Recent Events

    • 05 Nov 2024 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
    • 05 Nov 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
    • 12 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top